As populations age worldwide, the decline of the immune system, a process known as immunosenescence, has become a critical biomedical challenge. This decline leads to increased susceptibility to ...

Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off-the-shelf' T Cell Receptor-based Natural Killer (TCR-NK) cell ...

The NF-κB-inducing kinase (NIK), a molecule pivotal for immune system development and function, shows significant yet complex potential as a therapeutic target. The comprehensive review, published by ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...

Engineered HLA-independent T cell receptors have eliminated kidney, ovarian and pancreatic tumours in laboratory studies by detecting minute levels of CD70 which may open a route to broader solid ...

Researchers at Atrium Health Wake Forest Baptist have shown that engineered macrophages can infiltrate brain tumor sites, recognize cancer cells, and destroy them in preclinical mouse models, ...

Oslo, Norway, 09 March 2026 - Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, toda ...

T-cell therapy is based on engineered immune cells that find and destroy cancer cells. However, sometimes these cells also attack healthy tissues, causing side effects. An international team of ...

CAAR-T therapy may eliminate FVIII inhibitors in hemophilia A, potentially improving replacement treatment effectiveness, a study shows.

Researchers engineer CAR-astrocytes to target and remove amyloid plaques in Alzheimer’s, showing a 50% reduction in brain ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.